The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TARA | +113.57% | -74.35% | -23.8% | -82% |
| S&P | +13.19% | +87.83% | +13.42% | +106% |
Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.09M | -4.8% |
| Market Cap | $167.83M | 344.6% |
| Market Cap / Employee | $5.09M | 0.0% |
| Employees | 33 | 22.2% |
| Net Income | -$13.26M | -18.2% |
| EBITDA | -$14.67M | -19.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $12.55M | -75.8% |
| Accounts Receivable | $1.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.44M | -33.4% |
| Short Term Debt | $1.22M | 13.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -44.32% | 1.7% |
| Return On Invested Capital | -37.61% | -78.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$12.46M | -47.5% |
| Operating Free Cash Flow | -$12.45M | -47.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.33 | 0.89 | 0.74 | 1.16 | 414.43% |
| Price to Tangible Book Value | 1.33 | 0.89 | 0.74 | 1.16 | 414.43% |
| Enterprise Value to EBITDA | 1.84 | -3.79 | -0.60 | -3.74 | -227.57% |
| Return on Equity | -37.9% | -41.9% | -43.0% | -49.4% | -6.71% |
| Total Debt | $4.48M | $4.23M | $3.95M | $3.66M | -22.80% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
